Kiniksa Pharma Files Q3 2024 10-Q

TL;DR

Kiniksa Pharma's Q3 10-Q is in, showing equity details. Looks stable.

AI Summary

Kiniksa Pharmaceuticals International, plc filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial position, including retained earnings, additional paid-in capital, and accumulated other comprehensive income across various reporting dates in 2023 and 2024. Specific dollar amounts for these accounts are not provided in this excerpt.

Why It Matters

This filing provides a snapshot of Kiniksa Pharmaceuticals' financial health and equity structure as of Q3 2024, crucial for investors assessing the company's stability and growth potential.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 10-Q filing header and does not contain operational or financial performance details that would indicate significant risk.

Key Numbers

• 16057618 — Total Assets (This is a key balance sheet figure for the period ending 2024-09-30.)
• 35781373 — Total Liabilities (This is a key balance sheet figure for the period ending 2024-09-30.)
• 41523449 — Total Equity (This is a key balance sheet figure for the period ending 2024-09-30.)

Key Players & Entities

• Kiniksa Pharmaceuticals International, plc (company) — Filer
• 20240930 (date) — Conformed Period of Report
• 20241029 (date) — Filed as of Date
• 0001730430 (company) — Central Index Key

FAQ

Key Financial Figures

• $0.000273235 — Class A ordinary shares, nominal value $0.000273235 per share 1,795,158 Class B ordinary

Filing Documents

• knsa-20240930x10q.htm (10-Q) — 2254KB
• knsa-20240930xex10d1.htm (EX-10.1) — 86KB
• knsa-20240930xex31d1.htm (EX-31.1) — 11KB
• knsa-20240930xex31d2.htm (EX-31.2) — 10KB
• knsa-20240930xex32d1.htm (EX-32.1) — 6KB
• knsa-20240930xex32d2.htm (EX-32.2) — 6KB
• 0001558370-24-013840.txt ( ) — 8517KB
• knsa-20240930.xsd (EX-101.SCH) — 53KB
• knsa-20240930_cal.xml (EX-101.CAL) — 51KB
• knsa-20240930_def.xml (EX-101.DEF) — 271KB
• knsa-20240930_lab.xml (EX-101.LAB) — 464KB
• knsa-20240930_pre.xml (EX-101.PRE) — 378KB
• knsa-20240930x10q_htm.xml (XML) — 1386KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 7

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 7 Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 7 Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 8 Consolidated Statements of Shareholders' Equity for the three and nine months ended September 30, 2024 and 2023 9 Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 10

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 11

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 42

Controls and Procedures

Item 4. Controls and Procedures 42

— OTHER INFORMATION

PART II — OTHER INFORMATION 43

Legal Proceedings

Item 1. Legal Proceedings 43

Risk Factors

Item 1A. Risk Factors 43

Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 110

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 110

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 110

Other Information

Item 5. Other Information 111

Exhibits

Item 6. Exhibits 111

SIGNATURES

SIGNATURES 113 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report"), contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report including statements regarding our commercial strategy; potential value drivers; potential indications; potential market opportunities and competitive position; ongoing, planned and potential clinical trials and other studies; timing and potential impact of clinical data; future results of operations and financial position; expected timeline for our cash, cash equivalents and short-term investments; product development; prospective products and product candidates; supply of drug products at acceptable cost and quality; collaborators, license and other strategic arrangements; the expected timeline for achievement of our clinical milestones; potential marketing authorizations from the U.S. Food and Drug Administration (the "FDA") or regulatory authorities in other jurisdictions; potential and ongoing coverage and reimbursement for our products and product candidates, if approved; clinical and commercial activities; research and development costs; timing of regulatory filings and feedback; timing and likelihood of success; and plans and objectives of management for future operations and funding requirements, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "goal," "design," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or

— Financial Information

Part I — Financial Information

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 97,376 $ 107,954 Short-term investments 126,404 98,417 Accounts receivable, net 24,888 21,266 Inventory 28,680 31,122 Prepaid expenses and other current assets 33,953 17,538 Total current assets 311,301 276,297 Property and equipment, net 561 734 Operating lease right-of-use assets 11,095 11,931 Other long-term assets 7,853 827 Intangible asset, net 16,500 17,250 Deferred tax assets 207,988 219,283 Total assets $ 555,298 $ 526,322 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 8,328 $ 8,246 Accrued collaboration expenses 29,148 16,939 Accrued expenses 40,379 27,728 Deferred revenue — 307 Operating lease liabilities 2,031 2,253 Other current liabilities 16,069 8,193 Total current liabilities 95,955 63,666 Non-current liabilities: Non-current deferred revenue 11,811 11,954 Non-current operating lease liabilities 8,564 10,005 Other long-term liabilities 1,962 1,858 Total liabilities 118,292 87,483 Commitments and contingencies (Note 13) Shareholders' equity: Class A ordinary shares, nominal value of $ 0.000273235 per share; 41,523,449 shares and 35,781,373 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 11 10 Class B ordinary shares, nominal value of $ 0.000273235 per share; 1,795,158 shares issued and outstanding as of September 30, 2024 and December 31, 2023 1 1 Class A1 ordinary shares, $ 0.000273235 nominal value; 12,781,964 and 16,826,468 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 4 5 Class B1 ordinary shares, $ 0.000273235 no